LEVERKUSEN, Germany--Bayer here has announced a collaboration with Genzyme to accelerate identification of drug development targets. Candidates will come from Genzyme's small-molecule compound library and be analyzed with Bayer's high-speed robotic screening equipment. The deal could be worth as much as $35 million to Genzyme in fees and milestone payments, the company said.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.